Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Sumitomo Dainippon Pharma 1Q Net Y17.00B Vs Net Y11.21B
Sumitomo Dainippon Pharma Co. Ltd. (4506.TO) Japan 1st Quarter Ended June 30 GROUP 2026 2025 Revenue Y129.50 bln Y108.00 bln Operating Profit Y18.19 bln Y20.40 bln Net Profit Y17.00 bln Y11.21 bln Per share Earnings Y39.02 Y28.21 Results are based…
Sun Pharma Q1 net rises 27% to ₹2,895 crore
Sun Pharmaceuticals Industries Ltd. for the first quarter ended June 30, 2026 reported a 27% year-n-year growth in consolidated net profit to ₹2,895 crore. Sales income at ₹15,184 crore grew 10.1%. Global Innovative Medicines sales at…
Alnylam Pharma (ALNY) Q2 2026 Earnings Call Transcript
Thursday, July 30, 2026, at 8:30 a.m. ET Vice President of Investor Relations - Josh Brodsky Chief Executive Officer - Yvonne Greenstreet Chief Financial Officer - Jeff Poulton Chief Commercial Officer - Tolga Tanguler Chief Research and…
Sun Pharma on track to complete Organon transaction by Q4, says management
Sun Pharmaceutical Industries Ltd expects to complete its $11.75 billion acquisition of US-based Organon in the fourth quarter of financial year 2027, top management with the drugmaker said, after the company shared its financial performance for…
Sun Pharma posts higher quarterly profit on strong demand
Sun Pharmaceutical Industries reported a 27 per cent rise in quarterly profit on Friday, boosted by strong demand for its high-margin specialty medicines used to treat chronic and complex conditions. Consolidated net profit rose to ₹2,895…
Torrent Pharma to cut medical representative strength to around 9,000 this year
Torrent Pharmaceuticals, the flagship entity of Gujarat-based Torrent Group, plans to reduce its medical representative (MR) strength to around 9,000 from the current combined field force of 9,400 as it integrates the operations of JB Chemicals &…
Strides Pharma Science Q1 PAT rises 56.7% to ₹165.5 cr
Strides Pharma Science Ltd on Friday reported a 56.7 per cent rise in profit after tax at Rs 165.5 crore in the first quarter ended June 30, on the back of strong growth in markets excluding the US. The company had posted a profit after tax of Rs…
Pfizer (NYSE: PFE) Offers Value And Income While Eli Lilly (NYSE: LLY) Bets On Growth In Diverging Pharma Investment Race
Pfizer (NYSE: PFE) and Eli Lilly and Company (NYSE: LLY) represent two sharply different investment cases within the pharmaceutical sector, appealing to entirely different types of investors. Pfizer has seen its valuation compress significantly in…
Vestor Capital LLC Acquires 71,688 Shares of Royalty Pharma PLC $RPRX
Vestor Capital LLC boosted its stake in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 597.4% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 83,688 shares of the…
Reversing Alzheimer's - The Forgotten Causes and Cures Big Pharma Buried
It's not the mind fading; it's the neurons refusing to speak under the weight of blocked blood, stale sleep, and chemical noise. Remove the interference, and even the quietest thoughts begin to whisper again. If you're being told you can get all…
Q1 Results Today : Bajaj Finserv, Sun Pharma, GAIL, Dixon Tech, Aether, Glenmark Q1 profit rise, Urban Company logs Q1 loss, Maruti Suzuki, ITC, IOC Q1 profit declines
Q1 Results Today, 31st July 2026 Updates: Get real-time Q1 FY27 earnings updates, profit growth, revenue numbers and management outlook from 20 Microns, Aadhar Housing Finance, Aarti Drugs, ABB India, Sanghvi Movers. EARNINGS IMPACT TODAYGAINERS:…
Bajaj Finance Q1 Profit Surge Boosts Indian Markets, FII Inflows Continue
Indian stock market benchmarks Sensex and Nifty traded higher in early deals, propelled by a robust 6 per cent surge in Bajaj Finance shares following its impressive Q1 FY27 earnings, alongside sustained foreign fund inflows and declining crude oil…
Summit Therapeutics: Upgrading To Hold As Critical Approval Decision Approaches (SMMT)
Summit Therapeutics Inc. is upgraded from Sell to Hold as the FDA reviews its BLA for ivonescimab, with a decision expected by November 14, 2026. SMMT's pivotal HARMONI study showed statistically significant PFS but only a favorable trend in OS;…
XLV vs. IHE: Which Healthcare ETF Is the Better Buy?
The State Street Health Care Select Sector SPDR ETF (XLV -0.44%) provides broad healthcare exposure at a lower cost, while the iShares U.S. Pharmaceuticals ETF (IHE -0.91%) offers a concentrated bet on U.S. drugmakers. While both funds target…
Rising US Yields May Complicate RBI's Rate and Rupee Strategy
This article is for subscribers only. I'm Pratigya Vajpayee in Mumbai, wrapping up a roller-coaster week for the markets. Asian stocks are off to a flying start on the last trading day of the month, thanks to a big rebound in AI-linked shares. At…
Receive a Daily briefing on Pharma Industry News
Get Started